News

The challenge study, in which 84 adults completed the challenge after receiving two doses of the vaccine or placebo, showed that the vaccine was generally well tolerated, and

Trius said that Torezolid phosphate (TR-701) is currently in Phase 3 clinical testing in patients with acute bacterial skin and skin structure infections (ABSSSI). Trius has licensed patents

With this acquisition, Three Rivers is expected to serve as the commercial and operational cornerstone for Kadmon. Three Rivers is known to currently market several products for the

Adjusted net income decreased 14% to $1,313m for the third quarter of 2010, compared to $1,518m for the third quarter of 2009. The decrease in adjusted net income

Ofatumumab is a novel human monoclonal antibody. It targets a part of the CD20 molecule on B-cells encompassing an epitope on the small and large loops. In the

As per the terms of the option agreement, Celtic Therapeutics has an exclusive option to acquire and license rights to Resolvyx’s RX-10045, in all eye indications. Additionally, Celtic

Reflex study was conducted with the serum-free formulation of Rebif 3, which was first introduced in 2007 and is now available in all EU countries, Australia, Canada and

Specifically, the Teracles study will evaluate whether once daily oral Teriflunomide 14 or 7mg, in patients treated for at least 6 months on a stable dose of IFN

HealthStream has posted a net income of $796,000 for the third quarter 2010, compared to a net income of $1.02m in the third quarter of 2009. HealthStream has